Market Pulse: Digital assets ping-ponged after chatter about Ripple’s XRP supply shrinking to Bitcoin-like scarcity and short-term Bitcoin holders hitting break-even.
Key Movers: Ripple’s XRP squeeze narrative (newsBTC), Crinetics Pharma’s FDA green light (Yahoo Entertainment), and Roche’s sixth-generation Troponin T data (GlobeNewswire) stole the spotlight.
Macro & Politics: FDA’s October 19 verdict on Amgen/AZ Tezspire underscores the regulatory grind fueling biotech valuations, while SPAC debates highlight public-market policy friction.
What’s Next: Eyes on the FDA docket—especially the Tezspire decision—and potential SPAC-related legislation that could reshape public offerings.
📈 Breaking Financial News
XRP Short Squeeze: Analyst Reveals Available Trading Supply Could Fall To Bitcoin’s 21 Million
Ripple’s XRP might be trending towards a short squeeze as new analysis suggested its available trading supply could shrink to levels comparable to Bitcoin’s 21 million cap. XRP commentator Chad Steingraber, in a post on social media platform X, argued that th… Read more
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug
We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the companies… Read more
Bitcoin STHs hit break-even: Is a BTC price bottom close?
Are Bitcoin’s stressed short-term holders signaling another bottom? Read more
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Basel, 30 September 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Troponin T test for diagnosing heart attacks. Presented at th… Read more
A High Probability FDA-Approval Candidate For October
An FDA Decision for Amgen and AstraZeneca’s Tezspire in CRSwNP is slated for October 19: Why approval looks likely. Read more
Ditch Tesla, Buy This $20 “AI Powerhouse”
Forget overhyped AI stocks. Warren Buffett and Elon Musk are betting on the backbone of the AI revolution: ENERGY. Now, you can profit from their secret with a little-known $20 stock.
🔍 Market Analysis & Insights
The Case For SPACs
Neither inherently good nor bad, SPACs can play a vital role in revitalizing the American public markets, which have been shrinking for several decades now. Read more
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf pr… Read more
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf p… Read more
A drug made from marijuana reduced back pain in a large study
WASHINGTON (AP) — An experimental medication made from marijuana successfully reduced back pain in a new study, offering further support for the drug’s potential in treating one of the most common forms of chronic pain. The 800-patient study by a German drugm… Read more
Microneedle Drug Delivery Systems Market Size to Surpass USD 11.6 Billion by 2032 Fueled by Chronic Disease Burden and Demand for Patient-Friendly Solutions | S&S Insider
North America leads the market, while Asia Pacific posts the fastest growth as governments invest in next-gen drug delivery infrastructure. North America leads the market, while Asia Pacific posts the fastest growth as governments invest in next-gen drug deli… Read more
[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. Now, you have the rare chance to profit BEFORE the upcoming IPO.
💰 Investment Opportunities
LLY Stock Set For A 20% Breakout?
Over the past 10 years, the stock has attracted buying interest at this level 5 times and subsequently achieved an average peak return of 22.4%. Read more
Global Leukapheresis Market to Reach USD 491 Million by 2032 Fueled by Cell Therapy Advancements | S&S Insider
Strong growth driven by rising cases of blood disorders, expanding CAR-T therapy adoption, and rapid innovation in leukapheresis devices and disposables. Strong growth driven by rising cases of blood disorders, expanding CAR-T therapy adoption, and rapid inno… Read more
Moonlake: What’s Happening With MLTX Stock?
While both studies technically met their primary and essential secondary endpoints using a pre-determined treatment policy method, the extent of the results… Read more
Outlook Therapeutics Provides Update on Type A Meeting with FDA
ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the… Read more
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
– Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant – Read more
Market Commentary
Most are fixated on the XRP supply crunch and Bitcoin short-term holders hitting break-even, but what everyone’s missing is how biotech approval calendars are the real market rocket fuel. Crinetics Pharma’s 35% FDA win (Yahoo Entertainment) and Roche’s high-sensitivity Troponin T data (GlobeNewswire) spotlight how regulatory catalysts can deliver hell of a punch to equity valuations. And don’t sleep on the upcoming FDA verdict for Amgen/AZ Tezspire—it could make or break sector sentiment.
It might look odd to link SPACs with microneedle drug-delivery systems, but there’s a play here. “The Case For SPACs” (Forbes) and the projected $11.6B microneedle market (GlobeNewswire) reveal a thesis: SPAC vehicles are circling cutting-edge medtech firms hungry for patient-friendly delivery platforms. That setup could route fresh capital into next-gen healthcare innovators faster than traditional IPO corridors.
So here’s the action: stake out names tied to key FDA dates and SPAC sponsors with healthcare targets—think microdelivery and theranostics. Avoid getting lost in crypto FOMO; the regulatory calendar and special purpose vehicles are carving the real path for smart money. Keep portfolio firepower ready for those trigger events.